Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
2(22%)
Results Posted
33%(1 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_3
3
33%
Ph phase_4
2
22%
Ph phase_1
1
11%
Ph phase_2
1
11%

Phase Distribution

1

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
3(42.9%)
Phase 4Post-market surveillance
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(3)
Completed(3)
Terminated(1)
Other(2)

Detailed Status

Completed3
unknown2
Active, not recruiting2
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (14.3%)
Phase 21 (14.3%)
Phase 33 (42.9%)
Phase 42 (28.6%)

Trials by Status

not_yet_recruiting111%
unknown222%
terminated111%
completed333%
active_not_recruiting222%

Recent Activity

2 active trials
Showing 5 of 9
active_not_recruitingphase_2

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

NCT03519464
terminated

Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department

NCT06229353
completed

Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection

NCT06752083
completedphase_4

HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

NCT04982614
completedphase_1

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

NCT05496231
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03519464Phase 2

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

Active Not Recruiting
NCT06229353

Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department

Terminated
NCT06752083

Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection

Completed
NCT04982614Phase 4

HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

Completed
NCT05496231Phase 1

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

Completed
NCT06536855Phase 4

Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda

Not Yet Recruiting
NCT06207175Phase 3

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Unknown
NCT05662020Phase 3

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Active Not Recruiting
NCT05580341Phase 3

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Unknown

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9